Moderna Inc. (NASDAQ: MRNA) is an American biotechnology company headquartered in Cambridge, Massachusetts, founded in 2010 by Derrick Rossi and Noubar Afeyan. The company pioneered nucleoside-modified mRNA technology and gained global recognition for its COVID-19 vaccine (Spikevax). Beyond infectious disease vaccines, Moderna has established a robust pipeline spanning oncology, rare diseases, cardiovascular disease, and — critically for NeuroWiki — neurodegenerative disorders. The company's mRNA platform enables direct intracellular delivery of genetic instructions for protein production, offering novel therapeutic approaches for diseases where protein deficiency or dysfunction plays a key role[1].
| Attribute | Details |
|---|---|
| Headquarters | Cambridge, MA |
| Founded | 2010 |
| IPO | 2018 (NASDAQ: MRNA) |
| Market Cap | ~$15-20B (2026) |
| CEO | Stéphane Bancel |
| Employees | ~5,000+ |
| Focus | mRNA therapeutics, vaccines, protein replacement |
| Year | Milestone |
|---|---|
| 2010 | Founded by Derrick Rossi and Noubar Afeyan |
| 2013 | Partnership with AstraZeneca for cardiovascular mRNA |
| 2015 | Advanced clinical trials for mRNA therapeutics |
| 2018 | IPO on NASDAQ (raised $600M) |
| 2020 | COVID-19 vaccine (mRNA-1273) authorized for emergency use |
| 2021 | Spikevax received full FDA approval |
| 2022 | Expanded pipeline into rare diseases and neurodegeneration |
| 2023 | Multiple Phase 3 programs in influenza, RSV, and cancer |
Moderna's platform uses nucleoside-modified mRNA delivered via lipid nanoparticles (LNPs) to instruct cells to produce therapeutic proteins. This approach offers several advantages over traditional small molecule or protein drugs:
The LNP delivery system protects mRNA from degradation and enables cellular uptake. Current research focuses on improving brain delivery for neurological applications, as LNPs can be engineered to cross the blood-brain barrier more efficiently[2].
Moderna has initiated programs targeting Alzheimer's disease and Parkinson's disease, leveraging its mRNA platform:
| Program | Mechanism | Indication | Stage | Notes |
|---|---|---|---|---|
| mRNA-1647 | Therapeutic vaccine | Alzheimer's | Preclinical | Targeting tau pathology |
| mRNA-1684 | Protein replacement | Parkinson's | Preclinical | GDNF delivery via mRNA |
| mRNA-XXXX | Neurotrophic factor | ALS | Discovery | BDNF delivery |
Therapeutic Vaccines: mRNA-encoded antigens can stimulate immune responses against pathological proteins like amyloid-beta or tau in Alzheimer's disease, or alpha-synuclein in Parkinson's disease.
Protein Replacement: mRNA can encode missing or deficient proteins. For example:
Enzyme Replacement: For lysosomal storage diseases that can affect the brain, mRNA-encoded enzymes may be delivered systemically and cross the blood-brain barrier.
| Program | Area | Indication | Phase |
|---|---|---|---|
| Spikevax (mRNA-1273) | Vaccine | COVID-19 | Approved |
| mRNA-1649 | Vaccine | RSV | Phase 3 |
| mRNA-1010 | Vaccine | Influenza | Phase 3 |
| mRNA-4157 | Oncology | Melanoma | Phase 2 |
| mRNA-3705 | Rare Disease | Methylmalonic acidemia | Phase 2 |
Moderna has established strategic partnerships to advance its pipeline:
| Partner | Focus Area | Deal Value |
|---|---|---|
| Merck | Oncology, vaccines | $1B+ |
| Vertex | Cystic fibrosis mRNA | $275M |
| NIH | Vaccine research | Multiple grants |
| DARPA | Pandemic prevention | $400M+ |
| AstraZeneca | Cardiovascular | $200M |
Moderna's therapeutic vaccine approach for Alzheimer's disease targets pathological proteins including:
The advantage of mRNA vaccines is the ability to stimulate both antibody and T-cell responses against these targets, potentially modifying disease progression.
For Parkinson's disease, Moderna is exploring:
Moderna has early-stage programs for ALS focusing on neurotrophic factor delivery to support motor neuron survival.
| Metric | Value |
|---|---|
| Stock Exchange | NASDAQ |
| Ticker | MRNA |
| Market Cap | ~$15-20B |
| 2023 Revenue | ~$6.7B (primarily COVID vaccine) |
| R&D Budget | ~$4B annually |
| Cash Position | Strong (>$15B) |
Moderna competes in the mRNA space with: